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cancer patients in the home care setting  
 
Introduction 
Making prognostic predictions is one of the core skills of physicians engaged in 
end-of-life care,1 and is a component of approaches to multidisciplinary palliative care.2 
In addition, patients with advanced cancer face difficult decisions regarding their 
treatment and choices related to end-of-life care.3,4 Accurately predicting prognosis is 
therefore helpful not only for patients and their families, but also for healthcare 
professionals who support their decision making,5 especially those in the home care 
setting. 
In general, it is difficult to predict the prognosis of advanced cancer patients, 
especially those in the home care setting, because of limitations in the number of blood 
tests and radiological evaluations performed. Clinicians usually predict prognoses based 
on their own experience. A previous study revealed that prognostic prediction tools 
improved the accuracy of physicians’ predictions.6 Several prognostic prediction tools 
have been examined for cancer patients, for example the Palliative Prognostic Index 
(PPI),7 Cancer Prognostic Scale,7 Palliative Performance Scale,8 Palliative Prognostic 
Score (PaP score),9 Palliative Prognostic Score with Delirium (D-PaP score),10 Japan 
Palliative Oncology Study-Prognostic Index (J-POS-PI),11 and Prognosis in Palliative 
Care Study model,12 and each was properly validated. These tools are intended for use 
in assessing inpatient and ambulatory patients, and the appropriateness of their 
application to advanced cancer patients in the home care setting is uncertain.  
The PPI, which resulted in significant improvement in prognostication,6 was defined 
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based on performance status assessment using the Palliative Performance Scale 
(PPSv2),8 oral intake, and the presence or absence of dyspnea at rest, edema, and 
delirium. The PPI was developed and successfully validated for cancer patients in 
palliative care units by Morita et al in Japan.13 
The PPI does not require blood tests or radiological evaluation, and would therefore 
be very useful for cancer patients in the home care setting as compared to other 
validated prognostic prediction tools. Each PPI component is assigned an individual 
score, and these are added to derive the overall score. The final PPI score classifies 
patients into 1 of 3 groups: those with survival predicted to be shorter than 3 weeks (PPI 
≥6), shorter than 6 weeks (PPI ≥4), or longer than 6 weeks (PPI <4). 
Previous studies14 were performed prospectively and did not clarify the usefulness of 
the PPI in the home care setting. The aims of this study were thus to prospectively 
determine the sensitivity and specificity of the PPI in the home care setting and to 
evaluate the association of each PPI component with 3 and 6 weeks’ prognostic 
prediction. 
 
Methods 
Our study population included all advanced cancer patients who received home 
visiting services regularly from Yamato Clinic between April 2010 and June 2012, and 
who died at home or in the hospital. Yamato Clinic provides ambulatory care and home 
visiting services for community residents, with 3 doctors (including one researcher: JH) 
specialized in family medicine and palliative care. The 3 doctors (including one 
researcher: JH) had trained to assess the PPI components and used the PPI in their usual 
practice. We recorded patients’ background information and prospectively assessed the 
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components of the PPI at the first home visit: PPS score, oral intake, and the presence or 
absence of dyspnea at rest, edema, and delirium. One researcher (JH) calculated the PPI 
score and actual survival time when each patient died. Subsequently, we calculated 
overall sensitivity, specificity, and area under the curve (AUC) of the PPI. Survival 
predictions were defined as mentioned above: less than 3 weeks for PPI ≥6, and less 
than 6 weeks for PPI ≥4. In addition, we conducted univariable analyses to assess 
significant differences between 3- or 6-week survival and each PPI component.  
To determine the association of each PPI component with 3 and 6 weeks’ prognostic 
prediction, we used Student's t-test for continuous variables and Pearson's chi-square 
test or Fisher's exact test for categorical variables. All analyses were conducted using 
SPSS-J, ver.21.0, IBM, Tokyo, Japan. 
This study was not confirmed by the institutional review board, but our study was 
performed according to the ethical guidelines for Epidemiological Research by the 
Ministry of Health, Labour and Welfare of Japan, and written informed consent was not 
necessary. 
This study was conducted in conformity with the Declaration of Helsinki and was 
carried out with special regard for the protection of individual data. 
 
Results 
Sixty-six patients (48 males) were included in this study. Table 1 shows patient 
background information in detail. The mean patient age was 75.6 years, with 28 patients 
(42.4%) in their 70s and 15 patients (22.7%) in their 80s. The primary cancer site was 
the lung in 17 patients (15.8%), the stomach/esophagus in 12 patients (18.2%), and the 
colon/rectum/anus in 10 patients (15.2%).  
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The mean survival time after the first home visit was 72.9 days. Survival time was 
shorter than 3 weeks in 20 patients (30.3%) and shorter than 6 weeks in 34 patients 
(51.5%). Table 2 shows PPI scores and 3-week survival, and Table 3 shows PPI scores 
and 6-week survival. Eighteen patients (27.3%) had PPI scores ≥6, while 33 (50%) had 
PPI scores ≥4. Twelve patients with PPI scores ≥6 survived for less than 3 weeks, while 
24 patients with PPI scores ≥4 survived for less than 6 weeks.  
Table 4 shows the accuracy of the PPI for advanced cancer patients in the home care 
setting. Three-week survival was predicted with a sensitivity of 60% (95% CI, 39−78%), 
a specificity of 86.9% (95% CI, 74−94%), a positive predictive value of 66.7%, and a 
negative predictive value of 83.3%; the AUC was 74% (95% CI, 59–88%). Six-week 
survival was predicted with a sensitivity of 70.6% (95% CI, 54−83%), a specificity of 
71.9% (95% CI, 55−84%), a positive predictive value of 72.7%, and a negative 
predictive value of 69.7%; the AUC was 67% (95% CI, 54–81%). 
 Table 5 shows the association of each PPI component with 3 and 6 weeks’ prognostic 
prediction. We conducted univariable analyses concerning PPI components for patients 
who survived less than 3 weeks and less than 6 weeks. These analyses found that PPS, 
oral intake, dyspnea at rest, and delirium were statistically significant for patients who 
survived less than 3 weeks and less than 6 weeks.  
 
Discussion 
This study demonstrated three important findings. First, the sensitivity of the PPI for 
advanced cancer patients in the home care setting was lower than for advanced cancer 
patients in palliative care units. Morita et al13 reported that the sensitivity of the PPI for 
advanced cancer patients in the hospice setting who survived less than 3 weeks and less 
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than 6 weeks was 83% and 79%, respectively. This finding is same as that of our 
previous retrospective study.15 Maltoni et al16 also reported a prospective comparison 
between several prognostic scores, including the PPI, in the hospice setting. They found 
that the sensitivity and specificity of PPI scores ≥5 in patients who survived for less 
than 3 weeks in the hospice setting were 73.7% and 67.1%, respectively. To the best of 
our knowledge, however, our study is the first to prospectively reveal the usefulness of 
the PPI for advanced cancer patients in the home care setting, while also pointing out 
the limitations of the utility of the PPI in this population and setting. 
One possible reason for the discrepancy in PPI sensitivity between advanced cancer 
patients in the hospice setting and those in the home care setting is the differential 
prevalence of PPS ≤20 and delirium, which are the most heavily weighted scores in the 
PPI scoring system. In our study, the prevalence of PPS ≤20 in the home care setting 
was 4.5%, whereas Morita et al13 and Maltoni et al16 reported prevalence of 23% and 
41.3%, respectively, in the hospice setting. This discrepancy suggests the possibility that 
home visiting services tend to be started at early stages for patients with advanced 
cancer, because whereas the median duration of survival was 40 days in our study, 
Morita et al13 reported 27 days and Maltoni et al16 reported 22 days in the hospice 
setting. Regarding the prevalence of delirium, our study revealed a prevalence of 18.2% 
in the home care setting, whereas Morita et al13 and Maltoni et al16 reported prevalence 
of 38% and 28.2%, respectively, in the hospice setting. This discrepancy may have two 
causes. First, we may have underdiagnosed delirium because we did not use routinely a 
specific assessment tool for its screening. Second, patients who have delirium may tend 
not to transfer from hospital to home care because management of delirium is 
commonly difficult in the home care setting. The prevalence of other symptoms in our 
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study, namely oral intake, edema, and dyspnea at rest, also differed compared to the 
hospice setting. In our study the prevalence of severely reduced oral intake, edema, and 
dyspnea at rest were 13.6%, 40.9%, and 16.7% respectively, although Morita et al13 
reported prevalence of 38%, 35.4%, and 18% and Maltoni et al16 reported prevalence of 
27.7%, 33%, and 24.4%, respectively. These discrepancies may suggest that patient 
background differs intrinsically between the home care setting and hospice setting. 
Therefore the low sensitivity of the PPI means that this instrument may not be suitable 
for detecting poor prognosis in patients with relatively good performance status, 
especially in the home care setting . In addition to the results above, we found that the 
specificity of PPI for advanced cancer patients in the home care setting was nearly 90% 
in our study for 3-week survival, the same as in our previous study.15 These results 
support our previous suggestion that the PPI might not be useful as a screening tool for 
poor prognosis in the home care setting because of its low sensitivity, but might be 
useful with PPI scores <6, predicting survival longer than 3 weeks.  
The second important finding of this study was that PPS, oral intake, dyspnea at rest, 
and delirium had statistically significant associations with survival durations of less than 
3 weeks and less than 6 weeks for advanced cancer patients in the home care setting, 
while edema showed no significant correlation. This finding is in accordance with the 
EAPC recommendations regarding prognostic factors.2 It is possible that no association 
was detected between edema and survival due to insufficient power resulting from the 
small sample size of this study. We must reevaluate this question using a larger sample 
size from this patient population before forming a definitive conclusion, because a 
previous study11 showed that edema was significantly related to patient survival in the 
hospital setting.  
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The last important finding of this study was that all 14 patients with normal oral intake 
survived longer than 3 weeks. One possible reason may be that the nutritional status of 
the current study subjects with normal intake was maintained better than that of subjects 
in previous studies using inpatient settings. In the home care setting, patients can eat 
their favorite foods whenever they want, making it more likely that they can maintain a 
normal oral intake, which may lead to prolonged survival. A corollary to this is that 
there may be several disadvantages to using oral intake as a factor in predicting 
prognosis in the inpatient setting; for example, patients may not be served meals they 
like, and they may not express their meal preferences as easily as in the home care 
setting. Therefore we may mistakenly judge that patients in the inpatient setting may 
have decreased oral intake when in another setting they would in fact have normal oral 
intake.  
This study has three limitations. First, our report may not be representative of 
advanced cancer patients in the home care setting because it was carried out in only one 
institution. Second, the population of this study was relatively small. These limitations 
restrict the generalizability of our results. Third, as we have already described above, we 
may have underdiagnosed delirium because we did not screen using a standardized 
specific assessment tool such as CAM (Confusion Assessment Method17). This may 
affect the accuracy of the PPI in the current study. To overcome these limitations, we 
should carry out a large multicenter study for advanced cancer patients using standard 
symptom assessment tools in the home care setting. 
In conclusion, this study showed that the PPI had a lower sensitivity for advanced 
cancer patients in the home care setting than for those in palliative care units, though the 
specificity of the PPI for advanced cancer patients in the home care setting was nearly 
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90% for 3-week survival. Further research is needed to develop more accurate 
prognostic prediction tools for use in the home care setting. 
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All patients (n=66)
n (%)
Gender Male 48 (72.7)
Female 18 (27.3)
Mean age (years ± SD✝) 75.6 ± 11.3
Range (years) 41–94
Age distribution 35–49 3 (4.5)
50–59 1 (1.5)
60–69 12 (18.2)
70–79 28 (42.4)
80–89 15 (22.7)
90– 7 (10.6)
Primary cancer site Lung 17 (25.8)
Stomach/Esophagus 12 (18.2)
Colon/rectum/anus 10 (15.2)
Kidney/bladder 6 (9.1)
Liver/Biliary system 6 (9.1)
Pancreas 4 (6.1)
Prostate 3 (4.5)
Brain 3 (4.5)
Breast 1 (1.5)
Blood 1 (1.5)
Others 3 (4.5)
✝Standard Deviation
Table 1 Patient background (n=66)
Table 2 PPI scores and 3-week survival
< 3 weeks' survival ≥3 weeks' survival Total
PPI ≥ 6 12✝ 6 18
PPI < 6 8 40 48
Total 20 46 66
✝ Number of patients surviving <3 weeks with PPI scores >6
Table 3 PPI scores and 6-week survival
< 6 weeks' survival ≥ 6 weeks' survival Total
PPI ≥ 4 24✝ 9 33
PPI < 4 10 23 33
Total 34 32 66
✝ Number of patients surviving <6 weeks with PPI scores >4
Table 4 Accuracy of PPI for advanced cancer patients in home care settings
< 3 weeks (%) < 6 weeks (%)
Sensitivity 60.0 70.6
Specificity 87.0 71.9
Positive Predictive Value 66.7 72.7
Negative Predictive Value 83.3 69.7
Area under the curve 74 67
Table 5 Univariable analyses for patients surviving <3 weeks and 6 weeks (n = 66)
n (%) n (%) P value n (%) n (%) P value
Mean age (years ± SD✝) 73.1 ± 10.7 76.6 ± 11.5 0.25a 72.4 ± 10.4 78.9 ± 11.4 0.019a
Sex male 15 (75.0) 33 (71.7) 0.785b 26 (76.5) 22 (68.8) 0.482b
female 5 (25.0) 13 (28.3) 8 (23.5) 10 (31.3)
10–20 3 (15.0) 0 0.01c 3 (8.8) 0 0.001c
30–50 16 (80.0) 36 (78.3) 30 (88.2) 22 (68.8)
60– 1 (5.0) 10 (21.7) 1 (2.9) 10 (31.3)
Oral intake Severely reduced 8 (40.0) 1 (2.2) P<0.01c 8 (23.5) 1 (3.1) 0.006c
Moderately reduced 12 (60.0) 31 (67.4) 23 (67.6) 20 (62.5)
Normal 0 14 (30.4) 3 (8.8) 11 (34.4)
Edema Present 11 (55.0) 16 (34.8) 0.125b 17 (50.0) 10 (31.3) 0.122b
Absent 9 (45.0) 30 (65.2) 17 (50.0) 22 (68.8)
Dyspnea at rest Present 8 (40.0) 3 (6.5) 0.002c 9 (26.5) 2 (6.3) 0.028b
Absent 12 (60.0) 43 (93.5) 25 (73.5) 30 (93.8)
Delirium Present 8 (40.0) 4 (8.7) 0.005c 11 (32.4) 1 (3.1) 0.002b
Absent 12 (60.0) 42 (91.3) 23 (67.6) 31 (96.9)
a:Student's t-test
b:Pearson's chi-square test
c:Fisher's exact test
✝Standard Deviation
Variable
Palliative Performance
Scale(PPSv2)8)
< 3 weeks' survival
(n = 20)
≥ 3 weeks' survival
(n = 46)
< 6 weeks' survival
(n = 34)
≥ 6 weeks' survival
(n = 32)
